Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data
- PMID: 32348551
- PMCID: PMC7267152
- DOI: 10.1002/cpt.1872
Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data
Conflict of interest statement
The authors declared no competing interests for this work.
Comment in
-
Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data".Clin Pharmacol Ther. 2020 Aug;108(2):189. doi: 10.1002/cpt.1873. Epub 2020 May 20. Clin Pharmacol Ther. 2020. PMID: 32348544 Free PMC article. No abstract available.
Comment on
-
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12. Clin Pharmacol Ther. 2020. PMID: 32285930 Free PMC article.
References
-
- Joint ISAC and Elsevier statement on Gautret et al paper [PMID 32205204] <https://www.isac.world/news‐and‐publications/isac‐elsevier‐statement>. Accessed April 14, 2020.
-
- Paton, N.I. et al. Chloroquine for influenza prevention: a randomised, double‐blind, placebo controlled trial. Lancet Infect Dis. 11, 677–683 (2011). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous